Next-Gen Biotech Platforms This slice is part of the broader Healthcare & Biotech theme.
Next-Gen Biotech Platforms names often move on drivers that differ from the rest of Healthcare & Biotech. Isolating this segment keeps earnings logic and news flow aligned with one part of the value chain.
Membership is based on Next Big Trend classification under Healthcare & Biotech → Next-Gen Biotech Platforms. Save the list as a watchlist to track updates without rebuilding Screener filters.
| Company | |||||||
|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $127.5B | +1.06% | -0.87% | +12.51% | +21.12% | 65 |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of | $58.7B | +4.87% | +3.42% | +20.14% | +30.89% | 77 |
| TEVA | Teva Pharmaceutical Industries Limited | $45.7B | +3.97% | +13.07% | +31.69% | +103.36% | 89 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $33.0B | +5.90% | -5.99% | -41.49% | -48.37% | 51 |
| RPRX | Royalty Pharma plc | $32.6B | -0.40% | -3.10% | +48.76% | +60.47% | 59 |
| ZTS | Zoetis Inc. | $30.2B | +7.35% | +2.68% | -39.61% | -46.86% | 76 |
| WST | West Pharmaceutical Services, Inc. | $25.6B | +0.28% | +6.32% | +33.33% | +37.03% | 82 |
| UTHR | United Therapeutics Corporation | $22.9B | +1.38% | +8.99% | +12.71% | +22.33% | 86 |
| JAZZ | Jazz Pharmaceuticals plc | $15.0B | -7.32% | -9.17% | +28.48% | +58.53% | 45 |
| ASND | Ascendis Pharma A/S | $14.7B | +0.60% | -12.25% | +7.50% | +9.09% | 38 |
| NBIX | Neurocrine Biosciences, Inc. | $14.6B | -0.52% | -9.02% | +0.43% | +2.42% | 45 |
| SMMT | Summit Therapeutics Inc. | $14.3B | +4.98% | +3.47% | +0.57% | -24.64% | 77 |
| BBIO | BridgeBio Pharma, Inc. | $13.0B | -2.83% | -9.86% | -14.56% | +18.17% | 43 |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | +0.51% | +3.20% | +64.07% | +69.36% | 77 |
| CORT | Corcept Therapeutics Incorporated | $12.6B | +4.27% | +5.46% | +248.25% | +176.46% | 81 |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | -4.17% | -16.36% | -7.80% | +0.19% | 31 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.5B | -5.54% | -11.51% | -18.99% | +7.96% | 40 |
| AXSM | Axsome Therapeutics, Inc. | $10.3B | -6.08% | -20.26% | -7.82% | +41.82% | 24 |
| KRYS | Krystal Biotech, Inc. | $9.6B | +2.89% | -4.03% | +34.51% | +77.16% | 57 |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.4B | -2.24% | -24.18% | -5.48% | +69.87% | 18 |
| KYMR | Kymera Therapeutics, Inc. | $9.2B | +4.67% | -3.93% | +44.45% | +99.68% | 57 |
| PTGX | Protagonist Therapeutics, Inc. | $9.1B | +2.62% | -0.99% | +64.56% | +120.11% | 65 |
| TGTX | TG Therapeutics, Inc. | $8.1B | +1.99% | -0.04% | +85.74% | +54.88% | 68 |
| IONS | Ionis Pharmaceuticals, Inc. | $7.4B | +4.00% | -18.63% | -42.76% | -35.28% | 27 |
| SYRE | Spyre Therapeutics, Inc. | $7.0B | -8.05% | -3.40% | +161.57% | +384.67% | 58 |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.7B | -1.92% | +18.02% | +58.02% | +89.98% | 91 |
| IOVA | Iovance Biotherapeutics, Inc. | $6.7B | +2.85% | +79.61% | +435.53% | +544.05% | 98 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $6.2B | -2.21% | -11.17% | -15.19% | -9.43% | 40 |
| LGND | Ligand Pharmaceuticals Incorporated | $6.0B | -0.38% | +4.34% | +59.63% | +63.59% | 79 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | +5.26% | +4.31% | +93.41% | +108.25% | 79 |
| COGT | Cogent Biosciences, Inc. | $5.6B | -0.06% | -9.04% | -12.73% | -9.16% | 45 |
| ORKA | Oruka Therapeutics, Inc. | $5.6B | -2.85% | -10.41% | +170.90% | +263.00% | 42 |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.4B | +3.71% | -14.51% | +8.89% | +18.06% | 34 |
| PTCT | PTC Therapeutics, Inc. | $5.3B | +1.95% | -3.96% | -14.82% | +0.34% | 57 |
| DFTX | Definium Therapeutics, Inc. | $5.2B | -1.34% | -2.20% | +175.58% | +188.06% | 60 |
| MANE | Veradermics, Incorporated | $4.9B | +12.11% | +33.38% | +246.75% | — | 96 |
| TVTX | Travere Therapeutics, Inc. | $4.8B | -8.44% | -22.79% | +36.42% | +98.95% | 21 |
| DNTH | Dianthus Therapeutics, Inc. | $4.8B | -6.62% | -20.25% | +99.88% | +137.04% | 24 |
| ADPT | Adaptive Biotechnologies Corporation | $4.5B | -6.56% | +9.33% | +63.12% | +70.35% | 86 |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.4B | -0.85% | -28.70% | -25.95% | -7.18% | 12 |
| EWTX | Edgewise Therapeutics, Inc. | $4.3B | -5.65% | -8.95% | +57.40% | +154.46% | 46 |
| INDV | Indivior Pharmaceuticals, Inc. | $4.2B | +0.34% | +3.82% | -0.14% | +48.86% | 78 |
| RLAY | Relay Therapeutics, Inc. | $4.1B | -5.70% | -5.35% | +111.35% | +192.64% | 53 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.9B | +1.26% | -12.31% | +132.95% | +108.75% | 38 |
| TLX | Telix Pharmaceuticals Limited | $3.8B | +6.26% | -5.80% | +49.67% | +9.47% | 52 |
| LEGN | Legend Biotech Corporation | $3.8B | +0.27% | -2.97% | -14.35% | -42.19% | 59 |
| IDYA | IDEAYA Biosciences, Inc. | $3.7B | -3.35% | -3.58% | +4.45% | +34.54% | 58 |
| TNGX | Tango Therapeutics, Inc. | $3.7B | +2.45% | +1.88% | +168.74% | +244.57% | 74 |
| PLSE | Pulse Biosciences, Inc | $3.6B | +12.34% | -1.14% | +291.92% | +169.86% | 64 |
| VKTX | Viking Therapeutics, Inc. | $3.5B | -4.78% | -11.27% | -18.96% | -11.92% | 40 |
| XENE | Xenon Pharmaceuticals Inc. | $3.5B | -4.16% | -38.03% | -18.70% | -7.16% | 7 |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.4B | +0.22% | -9.81% | -10.65% | +4.89% | 43 |
| ELVN | Enliven Therapeutics, Inc. | $3.4B | -12.75% | -27.12% | +166.10% | +101.67% | 14 |
| DNLI | Denali Therapeutics Inc. | $3.4B | -2.75% | -9.11% | +17.81% | +24.28% | 45 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | +5.64% | +13.69% | -8.47% | +25.14% | 90 |
| RCUS | Arcus Biosciences, Inc. | $3.1B | -0.12% | -6.65% | +2.43% | +62.19% | 50 |
| DYN | Dyne Therapeutics, Inc. | $3.1B | +9.47% | -9.66% | -14.93% | +14.29% | 44 |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.8B | -7.00% | -1.30% | -38.50% | -34.34% | 64 |
| MBX | MBX Biosciences, Inc. | $2.7B | -9.01% | -15.37% | +68.80% | +236.96% | 33 |
| GRDN | Guardian Pharmacy Services, Inc. | $2.6B | -2.60% | -4.86% | +37.19% | +73.88% | 55 |
| BEAM | Beam Therapeutics Inc. | $2.5B | +4.90% | +5.46% | -7.29% | -4.81% | 81 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.5B | +0.68% | +2.35% | -14.14% | -11.10% | 75 |
| RXRX | Recursion Pharmaceuticals, Inc. | $2.5B | +5.83% | +37.97% | +6.60% | -28.41% | 97 |
| CLDX | Celldex Therapeutics, Inc. | $2.4B | -5.56% | -21.55% | +10.05% | +9.73% | 22 |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | -2.78% | -13.41% | +17.82% | +123.95% | 36 |
| GPCR | Structure Therapeutics Inc. | $2.3B | -7.70% | -35.42% | -63.28% | -55.67% | 8 |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | +1.61% | -2.00% | +7.64% | +51.66% | 61 |
| SLS | SELLAS Life Sciences Group, Inc. | $2.3B | -0.77% | -13.64% | +209.02% | +503.63% | 35 |
| AUPH | Aurinia Pharmaceuticals Inc | $2.2B | +5.18% | +3.35% | +4.39% | +44.41% | 77 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.2B | +4.65% | +3.14% | +9.62% | +17.45% | 77 |
| VERA | Vera Therapeutics, Inc. | $2.1B | -1.78% | -11.07% | -41.00% | -2.03% | 41 |
| ZBIO | Zenas BioPharma, Inc. | $2.1B | -3.66% | -12.35% | +55.94% | +118.61% | 38 |
| MLYS | Mineralys Therapeutics, Inc. | $2.1B | -1.10% | -20.24% | -35.60% | -37.66% | 24 |
| VRDN | Viridian Therapeutics, Inc. | $2.1B | -3.81% | -16.29% | -40.04% | -12.64% | 31 |
| AGIO | Agios Pharmaceuticals, Inc. | $2.0B | +0.03% | -5.44% | +16.86% | +52.05% | 53 |
| GENB | Generate Biomedicines, Inc. | $2.0B | +4.75% | -6.82% | +13.36% | — | 50 |
| LKFT | Lakefront Biotherapeutics | $1.9B | +1.23% | +10.89% | -9.08% | -13.83% | 88 |
| VIR | Vir Biotechnology, Inc. | $1.9B | +4.74% | +10.59% | +94.03% | +93.39% | 88 |
| TRVI | Trevi Therapeutics, Inc. | $1.9B | -5.18% | -17.10% | +5.35% | +34.32% | 29 |
| XERS | Xeris Biopharma Holdings, Inc. | $1.9B | +15.42% | +36.64% | +33.50% | +27.80% | 97 |
| SRPT | Sarepta Therapeutics, Inc. | $1.8B | +2.00% | -13.01% | -17.05% | -23.65% | 37 |
| PVLA | Palvella Therapeutics, Inc. | $1.8B | +4.76% | -7.73% | +32.58% | +85.40% | 48 |
| URGN | UroGen Pharma Ltd. | $1.8B | -11.04% | -12.81% | +57.26% | +112.52% | 38 |
| NTLA | Intellia Therapeutics, Inc. | $1.7B | +6.61% | +9.56% | +45.38% | -46.59% | 86 |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | +2.37% | +3.40% | -6.40% | -19.38% | 77 |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | -0.27% | -4.61% | +226.49% | +163.78% | 56 |
| STOK | Stoke Therapeutics, Inc. | $1.6B | -3.43% | -15.68% | -22.05% | -18.89% | 32 |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.5B | -3.47% | -9.72% | -19.13% | +2.97% | 43 |
| RAPP | Rapport Therapeutics, Inc. | $1.5B | -4.72% | -29.48% | +1.02% | +13.27% | 11 |
| NKTR | Nektar Therapeutics | $1.5B | -5.53% | -41.73% | -2.63% | -27.21% | 5 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | -40.82% | -41.71% | -16.85% | -19.64% | 5 |
| MAZE | Maze Therapeutics, Inc. | $1.5B | +2.57% | +9.23% | -34.56% | -5.19% | 86 |
| INBX | Inhibrx Biosciences, Inc. | $1.5B | -2.04% | -14.73% | +20.27% | +39.94% | 34 |
| AAPG | Ascentage Pharma Group International - American Depository Shares | $1.5B | -4.00% | -11.52% | -43.79% | -63.34% | 40 |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.4B | +1.71% | +7.50% | -32.70% | -49.84% | 84 |
| DRTS | Alpha Tau Medical Ltd. | $1.4B | -2.44% | -0.21% | +191.11% | +245.56% | 67 |
| TYRA | Tyra Biosciences, Inc. | $1.4B | -2.40% | -15.29% | -24.15% | +46.29% | 33 |
| OMER | Omeros Corporation | $1.4B | +6.56% | +6.67% | +15.42% | +351.71% | 83 |
| BCAX | Bicara Therapeutics Inc. | $1.3B | -0.74% | -24.24% | +3.98% | -2.78% | 18 |
| ORIC | Oric Pharmaceuticals, Inc. | $1.3B | -1.76% | -0.66% | +46.58% | -16.04% | 66 |
| DMRA | Damora Therapeutics, Inc. | $1.3B | +2.08% | -21.46% | -8.39% | +17.63% | 22 |
| PIII | P3 Health Partners Inc. | $1.3B | -22.17% | -40.79% | -49.37% | -80.26% | 6 |
| REPL | Replimune Group, Inc. | $1.2B | +2.68% | +1.36% | +0.57% | +7.60% | 72 |
| LBRX | LB Pharmaceuticals Inc | $1.2B | +0.62% | -19.52% | +67.21% | +147.47% | 26 |
| CSTL | Castle Biosciences, Inc. | $1.1B | -3.21% | +6.50% | -11.52% | +45.91% | 83 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.1B | +4.68% | +13.08% | -0.60% | +2.46% | 89 |
| JANX | Janux Therapeutics, Inc. | $1.1B | +8.62% | +4.02% | +33.26% | +62.86% | 79 |
| VOR | Vor Biopharma Inc. | $1.0B | +6.47% | -10.92% | +52.14% | +13.83% | 41 |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.0B | -1.90% | -28.07% | -34.31% | +33.59% | 13 |
| PCRX | Pacira BioSciences, Inc. | $986M | +44.03% | +44.32% | +40.30% | +55.10% | 97 |
| CRVS | Corvus Pharmaceuticals, Inc. | $977M | -3.49% | -18.70% | -48.63% | -43.49% | 27 |
| MLTX | MoonLake Immunotherapeutics | $971M | -5.17% | -17.91% | -17.91% | +18.90% | 29 |
| ABUS | Arbutus Biopharma Corporation | $961M | -5.17% | -17.58% | -12.27% | +0.96% | 29 |
| CGEM | Cullinan Therapeutics, Inc. | $953M | +0.13% | -26.05% | +50.05% | +163.67% | 15 |
| HELP | Helus Pharma Inc. | $898M | +0.85% | -8.10% | +44.25% | +88.50% | 47 |
| JBIO | Jade Biosciences, Inc. | $894M | +1.91% | -24.82% | -6.74% | +58.48% | 17 |
| PACB | Pacific Biosciences of California, Inc. | $892M | -8.27% | +83.46% | +24.60% | +54.30% | 98 |
| CADL | Candel Therapeutics, Inc. | $884M | -2.36% | -12.27% | +75.93% | +57.78% | 38 |
| RIGL | Rigel Pharmaceuticals, Inc. | $853M | +4.09% | +3.81% | +14.59% | +70.65% | 78 |
| SLBT | SL Science Holding Limited | $852M | -3.82% | -28.10% | -89.81% | -89.62% | 13 |
| AVTX | Avalo Therapeutics, Inc. | $843M | -8.94% | -20.55% | -24.83% | -4.01% | 24 |
| SGP | SpyGlass Pharma, Inc. | $829M | 0.00% | -8.75% | -5.61% | — | 46 |
| SANA | Sana Biotechnology, Inc. | $823M | -3.46% | -9.71% | -31.45% | -38.41% | 44 |
| LXRX | Lexicon Pharmaceuticals, Inc. | $810M | -7.69% | -16.83% | +46.09% | +17.48% | 30 |
| FDMT | 4D Molecular Therapeutics, Inc. | $800M | -2.49% | -1.19% | +77.73% | +37.99% | 64 |
| GYRE | Gyre Therapeutics, Inc. | $776M | -0.98% | +4.45% | -0.28% | -3.56% | 80 |
| ACRS | Aclaris Therapeutics, Inc. | $774M | -12.76% | -30.43% | +27.24% | +108.15% | 11 |
| DSGN | Design Therapeutics, Inc. | $774M | -5.59% | -21.28% | +24.20% | +67.87% | 23 |
| IMMX | Immix Biopharma, Inc. | $744M | -2.27% | -25.51% | +80.88% | +272.44% | 17 |
| SLDB | Solid Biosciences Inc. | $734M | +0.29% | -24.26% | +21.81% | +8.87% | 18 |
| CTKB | Cytek Biosciences, Inc. | $734M | -7.50% | +19.87% | +7.52% | +39.23% | 92 |
| FTH | Faeth Therapeutics, Inc. | $725M | -8.18% | -33.26% | -15.15% | -21.14% | 10 |
| OLMA | Olema Pharmaceuticals, Inc. | $722M | -4.92% | -26.85% | -68.72% | -27.12% | 14 |
| NVCT | Nuvectis Pharma, Inc. | $716M | -3.65% | -6.09% | +179.74% | +239.00% | 51 |
| OABI | OmniAb, Inc. | $715M | -1.64% | +21.27% | +158.92% | +173.71% | 93 |
| ZVRA | Zevra Therapeutics, Inc. | $701M | +14.01% | -5.56% | +27.12% | +7.05% | 53 |
| COLL | Collegium Pharmaceutical, Inc. | $698M | +0.32% | -3.62% | -52.29% | -33.32% | 58 |
| IRWD | Ironwood Pharmaceuticals, Inc. | $656M | +4.95% | -3.78% | +13.35% | +141.77% | 57 |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $640M | -22.40% | -46.62% | -51.86% | -46.75% | 3 |
| AURA | Aura Biosciences, Inc. | $638M | +7.39% | -6.44% | +20.00% | +7.39% | 51 |
| SGMT | Sagimet Biosciences Inc. - Series A | $621M | -2.30% | -19.26% | +50.84% | +22.16% | 26 |
| SLN | Silence Therapeutics Plc - American Depository Share | $610M | -7.33% | -25.92% | +62.17% | +87.81% | 16 |
| AQST | Aquestive Therapeutics, Inc. | $590M | +5.05% | -4.21% | -26.01% | -22.90% | 56 |
| CTMX | CytomX Therapeutics, Inc. | $588M | +0.39% | -23.28% | -39.67% | -23.74% | 20 |
| STTK | Shattuck Labs, Inc. | $568M | -11.29% | -2.93% | +63.56% | +149.79% | 59 |
| MPLT | MapLight Therapeutics, Inc. | $546M | -10.08% | -35.94% | +85.55% | — | 7 |
| EPRX | Eupraxia Pharmaceuticals Inc. | $542M | +3.04% | -7.67% | -1.19% | +23.92% | 48 |
| PHAT | Phathom Pharmaceuticals, Inc. | $542M | +4.77% | -13.38% | -56.30% | -34.39% | 36 |
| AGMB | AgomAb Therapeutics NV - ADRs representing one common share. | $530M | +6.07% | -34.86% | -38.02% | — | 8 |
| EOLS | Evolus, Inc. | $526M | +8.26% | -2.28% | +16.24% | +24.48% | 60 |
| MNPR | Monopar Therapeutics Inc. | $523M | +1.27% | -28.19% | +20.92% | -19.89% | 13 |
| CBIO | Crescent Biopharma, Inc. | $520M | +4.12% | -23.38% | +25.72% | +23.63% | 20 |
| NGNE | Neurogene Inc. | $513M | +2.92% | -26.91% | +28.16% | +2.21% | 14 |
| AUTL | Autolus Therapeutics plc | $508M | +1.69% | -7.65% | -9.05% | +2.84% | 48 |
| DRUG | Bright Minds Biosciences Inc. | $507M | +6.63% | -16.85% | -30.74% | -2.08% | 30 |
| MCTA | Charming Medical Limited | $504M | 0.00% | 0.00% | 0.00% | — | 73 |
| PBYI | Puma Biotechnology Inc | $499M | +8.20% | +12.21% | +72.94% | +96.75% | 89 |
| CAPR | Capricor Therapeutics, Inc. | $498M | -12.51% | -5.66% | -23.65% | -37.46% | 52 |
| ASMB | Assembly Biosciences, Inc. | $488M | +4.39% | -22.75% | -30.81% | -1.38% | 21 |
| CTNM | Contineum Therapeutics, Inc. | $473M | +1.98% | -8.73% | +17.06% | +17.47% | 46 |
| TKNO | Alpha Teknova, Inc. | $468M | -1.67% | +27.93% | +132.63% | +66.48% | 95 |
| ENTX | Entera Bio Ltd. | $466M | -6.99% | -4.66% | -28.30% | -26.40% | 55 |
| OVID | Ovid Therapeutics Inc. | $457M | +3.36% | -6.46% | +50.92% | +55.70% | 50 |
| DMAC | DiaMedica Therapeutics Inc. | $449M | +1.22% | +28.75% | +4.65% | +21.43% | 95 |
| TECX | Tectonic Therapeutic, Inc. | $444M | +3.50% | -18.46% | +11.84% | +51.89% | 27 |
| ZURA | Zura Bio Limited | $442M | -2.68% | -25.65% | -23.66% | -7.83% | 16 |
| SPRY | ARS Pharmaceuticals, Inc. | $434M | +3.93% | -16.40% | -63.69% | -61.93% | 31 |
| EIKN | Eikon Therapeutics, Inc. | $428M | +1.91% | -18.89% | -50.20% | — | 27 |
| AVIR | Atea Pharmaceuticals, Inc. | $415M | +0.39% | -0.58% | +44.26% | +73.40% | 66 |
| IRD | Opus Genetics, Inc. | $403M | +1.53% | -23.39% | +131.34% | +126.83% | 20 |
| GALT | Galectin Therapeutics Inc. | $394M | +1.03% | +1.03% | -5.29% | -16.88% | 71 |
| EDIT | Editas Medicine, Inc. | $385M | +10.69% | +9.43% | +41.46% | -30.12% | 86 |
| FENC | Fennec Pharmaceuticals Inc. | $379M | +5.00% | -5.22% | +39.09% | +16.16% | 54 |
| ARCT | Arcturus Therapeutics Holdings Inc. | $378M | +5.45% | -1.72% | +124.14% | +34.71% | 62 |
| ARTV | Artiva Biotherapeutics, Inc. | $377M | +1.61% | -33.40% | +61.77% | -42.22% | 9 |
| ENTA | Enanta Pharmaceuticals, Inc. | $367M | -3.55% | -1.57% | -20.74% | +10.62% | 63 |
| CCCC | C4 Therapeutics, Inc. | $367M | +7.12% | -7.06% | +65.45% | +39.82% | 49 |
| OBIO | Orchestra BioMed Holdings, Inc. | $362M | 0.00% | +2.41% | +43.37% | +105.17% | 76 |
| RLMD | Relmada Therapeutics, Inc. | $350M | -5.83% | -16.71% | -29.81% | +59.15% | 30 |
| TTRX | Turn Therapeutics Inc. | $346M | -9.98% | -10.31% | +204.57% | +71.43% | 42 |
| BNTC | Benitec Biopharma Inc. | $336M | -1.22% | -27.41% | -34.15% | -35.63% | 14 |
| LRMR | Larimar Therapeutics, Inc. | $318M | -9.80% | -30.65% | -29.92% | -44.61% | 11 |
| ABEO | Abeona Therapeutics Inc. | $316M | -1.79% | -14.68% | -6.26% | -5.90% | 34 |
| IPSC | Century Therapeutics, Inc. | $310M | -3.92% | -24.23% | +47.74% | +151.71% | 18 |
| INDP | Indaptus Therapeutics, Inc. | $306M | +5.46% | -1.95% | -59.87% | -68.35% | 61 |
| EVMN | Evommune, Inc. | $304M | -9.68% | -40.81% | -63.49% | — | 6 |
| PRLD | Prelude Therapeutics Incorporated | $300M | +5.99% | -16.70% | +34.14% | +519.49% | 30 |
| LXEO | Lexeo Therapeutics, Inc. | $297M | -8.50% | -25.92% | -67.47% | -59.78% | 16 |
| SRZN | Surrozen, Inc. | $296M | +1.26% | +52.65% | +31.37% | +111.47% | 98 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $293M | +4.76% | -26.46% | +95.56% | +60.98% | 15 |
| CATX | Perspective Therapeutics, Inc. | $288M | -3.62% | -3.97% | -3.27% | -31.09% | 57 |
| IKT | Inhibikase Therapeutics, Inc. | $287M | -1.50% | -15.45% | -3.90% | +18.67% | 33 |
| FATE | Fate Therapeutics, Inc. | $285M | -6.03% | -6.44% | +122.45% | +44.37% | 51 |
| CUVL | Clinuvel Pharmaceuticals Limited | $284M | -7.30% | -4.93% | -33.71% | -31.37% | 55 |
| FULC | Fulcrum Therapeutics, Inc. | $282M | +2.17% | -1.82% | -33.33% | -18.40% | 62 |
| XFOR | X4 Pharmaceuticals, Inc. | $277M | +2.83% | -14.41% | -27.25% | -12.35% | 34 |
| VNDA | Vanda Pharmaceuticals Inc. | $274M | -1.30% | -9.33% | -48.19% | -16.30% | 45 |
| ANIK | Anika Therapeutics Inc. | $273M | +2.51% | -6.72% | +103.75% | +115.40% | 50 |
| RCKT | Rocket Pharmaceuticals, Inc. | $272M | 0.00% | -26.44% | -27.07% | -24.48% | 15 |
| GLSI | Greenwich LifeSciences, Inc. | $270M | -2.65% | +9.76% | -21.32% | +44.43% | 87 |
| SABS | SAB Biotherapeutics, Inc. | $267M | 0.00% | -12.87% | -20.32% | +27.35% | 37 |
| IFRX | InflaRx N.V. | $265M | -6.98% | -21.95% | +58.42% | +8.84% | 22 |
| BCYC | Bicycle Therapeutics plc | $260M | +15.09% | +1.57% | -45.06% | -52.91% | 73 |
| AKBA | Akebia Therapeutics, Inc. | $258M | -7.39% | -15.36% | -50.24% | -71.89% | 33 |
| IVVD | Invivyd, Inc. | $256M | -12.27% | -7.05% | -70.80% | -56.02% | 49 |
| PALI | Palisade Bio, Inc. | $254M | +6.94% | -23.38% | -34.47% | -23.00% | 20 |
| NAUT | Nautilus Biotechnology, Inc. | $249M | +14.80% | +127.36% | +15.38% | +149.45% | 99 |
| LFCR | Lifecore Biomedical, Inc. | $248M | -1.38% | +57.70% | -21.15% | -6.11% | 98 |
| NNNN | Anbio Biotechnology | $244M | -16.04% | -28.42% | -84.50% | -84.96% | 13 |
| HITI | High Tide Inc. | $243M | -0.76% | +1.95% | -1.51% | -27.09% | 74 |
| STRO | Sutro Biopharma, Inc. | $243M | -7.04% | -19.97% | +23.34% | +67.88% | 25 |
| QTTB | Q32 Bio Inc. | $241M | +1.34% | -22.20% | -27.33% | -19.31% | 22 |
| CAMP | CAMP4 Therapeutics Corporation | $241M | -5.75% | -13.13% | -38.50% | +9.28% | 37 |
| PRQR | ProQR Therapeutics N.V. | $236M | -0.31% | -15.98% | -19.31% | -30.93% | 32 |
| SLGL | Sol-Gel Technologies Ltd. | $236M | -0.32% | +7.46% | +70.31% | +82.53% | 84 |
| LYEL | Lyell Immunopharma, Inc. | $231M | -5.94% | -28.61% | -71.70% | -52.30% | 12 |
| MGNX | MacroGenics, Inc. | $229M | +4.47% | -5.79% | +132.30% | +110.11% | 52 |
| LCTX | Lineage Cell Therapeutics, Inc. | $229M | +6.85% | -2.55% | -40.48% | -42.54% | 60 |
| CUE | Cue Biopharma, Inc. | $228M | +8.17% | -1.21% | +46.48% | -38.63% | 64 |
| KROS | Keros Therapeutics, Inc. | $223M | +5.19% | +6.98% | -41.31% | -25.13% | 83 |
| TRDA | Entrada Therapeutics, Inc. | $218M | +5.39% | -11.68% | -44.84% | -7.95% | 40 |
| PLX | Protalix BioTherapeutics, Inc. (DE) | $218M | +1.85% | +1.10% | +53.33% | +7.39% | 72 |
| SION | Sionna Therapeutics, Inc. | $215M | -0.20% | -35.70% | +35.09% | +95.01% | 8 |
| ELDN | Eledon Pharmaceuticals, Inc. | $215M | -0.40% | -10.79% | +64.24% | +71.98% | 41 |
| FOCL | EDAP TMS S.A. - American Depositary Shares, each representing One | $214M | -0.24% | +0.72% | +27.36% | +89.59% | 70 |
| FHTX | Foghorn Therapeutics Inc. | $209M | -0.99% | -55.46% | -62.96% | -55.56% | 2 |
| RNAC | Cartesian Therapeutics, Inc. | $204M | -4.14% | -16.31% | -2.15% | -31.04% | 31 |
| CMPX | Compass Therapeutics, Inc. | $203M | +15.91% | -51.56% | -48.04% | -28.45% | 2 |
| WHWK | Whitehawk Therapeutics, Inc. | $198M | -4.86% | -13.51% | +45.45% | +65.26% | 36 |
| NGEN | NervGen Pharma Corp. | $191M | -2.81% | -19.91% | -69.11% | -44.44% | 25 |
| BNR | Burning Rock Biotech Limited | $190M | -4.68% | +33.30% | -23.13% | +74.04% | 96 |
| ORMP | Oramed Pharmaceuticals Inc. | $186M | -3.56% | -9.03% | +62.97% | +94.34% | 45 |
| NKTX | Nkarta, Inc. | $184M | -12.62% | -19.93% | +21.62% | +7.66% | 25 |
| ANTX | AN2 Therapeutics, Inc. | $182M | -22.94% | -22.67% | +109.52% | +86.61% | 21 |
| IPHA | Innate Pharma S.A. | $182M | +3.85% | -16.92% | -7.43% | -16.92% | 30 |
| MSLE | Satellos Bioscience Inc. | $180M | -11.88% | -25.47% | +27.38% | +9.50% | 17 |
| MDWD | MediWound Ltd. | $176M | -7.25% | -8.53% | -32.07% | -28.51% | 47 |
| DTIL | Precision BioSciences, Inc. | $172M | +6.50% | -7.18% | +61.54% | +17.89% | 49 |
| ADCT | ADC Therapeutics SA | $167M | +53.10% | +55.86% | -50.99% | -61.89% | 98 |
| ABOS | Acumen Pharmaceuticals, Inc. | $167M | +4.90% | -25.17% | +1.42% | +10.31% | 17 |
| PEPG | PepGen Inc. | $163M | +14.91% | -13.25% | -59.75% | -46.20% | 36 |
| NBP | NovaBridge Biosciences | $157M | +2.95% | -17.46% | -64.95% | -68.08% | 29 |
| NERV | Minerva Neurosciences, Inc | $157M | -3.05% | -23.56% | -20.90% | +45.87% | 19 |
| MENS | Jyong Biotech Ltd. | $154M | -3.67% | +4.48% | -46.84% | -79.90% | 80 |
| VRXA | Veraxa Biotech AG | $154M | +11.50% | -23.64% | -73.46% | -72.93% | 19 |
| TARA | Protara Therapeutics, Inc. | $153M | +2.04% | -27.31% | -48.31% | -45.66% | 14 |
| MOLN | Molecular Partners AG | $151M | -1.53% | -7.89% | -11.68% | -1.03% | 48 |
| KZIA | Kazia Therapeutics Limited | $147M | -3.67% | -24.83% | +29.61% | +25.07% | 17 |
| VYGR | Voyager Therapeutics, Inc. | $146M | 0.00% | -23.20% | -37.66% | -53.60% | 20 |
| OTLK | Outlook Therapeutics, Inc. | $145M | +0.99% | -9.42% | -62.09% | -52.47% | 44 |
Companies classified under the Healthcare & Biotech theme and the Next-Gen Biotech Platforms sub-theme within Next Big Trend's catalog.
Yes. Signed-in users can save the current constituents from this page as a named watchlist.
No. It is a research universe for screening, not a recommendation.